Navigation Links
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
Date:4/7/2011

OSAKA, Japan and NORWOOD, Mass., April 7, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Boston Biomedical, Inc. ("BBI"), today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.

BBI608 is an orally administered, first-in-class, small molecule anti-cancer drug that targets highly malignant cancer stem cells as well as other heterogeneous cancer cells. In clinical trials to date, BBI608 has shown excellent safety, favorable pharmacokinetics, and encouraging signs of anticancer activity.  BBI608 is under phase I extension clinical studies in colorectal cancer and phase Ib/II trials in multiple solid tumor types.

Under the terms of the agreement, BBI will receive $15million of upfront payment and clinical trial support upon signing.  Based on the outcome of the clinical trials, DSP has the option to acquire exclusive rights for the development and commercialization for BBI608 in Japan. In addition, DSP has an exclusive negotiation right for the United States and Canada for a certain time.  During this option agreement period, DSP will pay a maximum of $55million for part of the development costs of BBI608 and for continuation of the option. Assuming DSP exercise the option for Japan, upon successful clinical development and commercialization of BBI608 in Japan, BBI could receive a maximum of approximately $100million in aggregate, including milestone payments associated with successful development and commercialization, in addition to running royalties.

Masayo Tada, President and chief executive officer of DSP, said, "DSP recognizes oncology as an area with high unmet medical needs and has already spent substantial effort, defining it as a major specialty area. We are delighted to enter into this strategic partnership with Boston Biomedical in the oncology area to d
'/>"/>

SOURCE Boston Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
3. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
4. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
5. CVS/pharmacy Debuts the "To Your Health" Program in Atlanta Bringing 60 Free Health Screening Events to the Community
6. CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste
7. Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
8. Harnessing Patients Good Intentions Can Cut 33% of Americas Pharmacy-Related Waste
9. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
10. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
11. ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... closes on Thursday, November 3, 2011.  In ... with the investment community at 5:00 p.m. Eastern Time ... to discuss the results of the quarter and other business developments. ...
... A potentially groundbreaking approach to predicting cancer patient ... electronic version of Science Magazine.  The paper describing the ... Letai and colleagues at Boston,s Dana Farber Cancer Institute. ... of the cancer cell to respond to chemotherapies. This ...
Cached Medicine Technology:Groundbreaking Approach to Predicting Cancer Patients' Response to Treatment Featured in Science Magazine 2
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has ... the college expand its reach and impact through innovative technologies and strategies. , “I ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... through research to improve treatment outcomes. This localized treatment seems to address ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Decatur County Memorial Hospital recently transitioned management companies to partner with Wound Care ... for their outpatient wound center. , Transitioning wound care management providers can ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Royal Brisbane and Women's Hospital (RBWH), Sydney struggles with ... in three wards were found with a bacterium ... skin. ,To prevent the spread, 12 patients ... cent burns) were shifted to Sydney hospital and some ...
... medical colleges in West Bengal continued to be paralysed ... stir against the Centre's decision to introduce OBC quota ... interns, housestaff and post graduate trainees in nine medical ... dental colleges boycotted classes as well as out patient ...
... drugs, used by patients with enlarged hearts// (dilated ... Scientists with the Multicenter defibrillators in Nonischemic ... sudden cardiac deaths with cardiomyopathy due to a ... these about, 229 patients were randomly selected to ...
... A study conducted by Cancer Research UK says 'Teens who tried ... never tried it to take up smoking' //.Again after 3 years ... Research UK said anti-smoking campaigns should focus on preventing children trying ... found around 14% of 11-year olds and 62% of 15-year olds ...
... Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd today said ... US-based Solutia Inc for 74.5 million dollars. // ... for purchasing 100 per cent stake in CarboGen ... in a statement., ,The acquisition includes other ...
... Ranbaxy Laboratories Limited today said the World Health Organistion ... (ARV) products in its pre-qualification list. // ... Efavirenz 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, ... a significant development. We strongly feel that Generic ARVs ...
Cached Medicine News:
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
... Oil is a clear, colorless oil ... of the UV-VIS spectrum. Resolve is ... viscosity, is non-drying and non-hardening, and ... Resolve contains no PCBs, eliminating toxicity ...
Medicine Products: